 The preclinical data indicate that Panobinostat restores the sensitivity of androgen-independent cells to bicalutamide Casodex and the combination has synergistic inhibitory activity. Here, we hypothesize that treatment of castration-resistant patients with Panobinostat will enhance the response to the second line hormone therapy with bicalutamide Casodex. In the proposed phase I study, the maximum tolerated dose of tri-weekly, intermittent oral Panobinostat at three different dose levels 60, 90, 120 mgweek in combination with Casodex 50mg PO will be determined; The following phase II study will evaluated the efficacies of 9-month treatments of the selected Panobinostat-Casodex combination and also a lower dose of Panobinostat. We expect that Casodex-Panobinostat combination treatment of castration-resistant patients will prevent biochemical andor metastatic disease progression of these patients compared to historical controls in the same time period. 